NCI B CELL LYMPHOMA VACCINE PHASE II TRIAL UNDER WAY
Executive Summary
NCI B CELL LYMPHOMA VACCINE PHASE II TRIAL UNDER WAY with custom-made vaccines procured from each participating patient's tumor, the National Cancer Institute announced May 24. The trial, which began in early April, will accrue 100 patients over the next two years. Larry Kwak, senior investigator in NCI's Biological Response Modifiers Program located in Frederick, Md., is leading the study. No company is participating in the trial but NCI eventually would outlicense the program.